Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 4;131(24):2617–2620. doi: 10.1182/blood-2018-04-840793

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by The American Society of Hematology

PMC Copyright notice

Figure 1. — Panoply of immunotherapies for malignant and nonmalignant hematological diseases. Passive immunotherapies consist of molecules from ex vivo activated cells that, following infusion or adoptive transfer, compensate for deficient immune functions. Active immunotherapies stimulate the patient’s immune system via a vaccine or inhibit an important checkpoint of T-cell activation. Antiviral CTLs, EBV (Epstein-Barr virus), CMV (cytomegalovirus), adenovirus, HHV6 (human herpesvirus 6), cytotoxic T cells; BiTEs and TriKEs, bi- and tri-specific T-cell engagers; DC, dendritic cells; DLI, donor lymphocyte injection following allogeneic hematopoietic cell transplantation; EBV CTL, nonengineered Epstein-Barr virus–specific cytotoxic T lymphocyte used to treat EBV⁺ lymphomas; ILC2, innate lymphocyte 2; mAbs, monoclonal antibodies; MDSCs, myeloid-derived suppressive cells; MSCs, mesenchymal stem cells; NKT, natural killer T cells; TIL, tumor-infiltrating T cells that have been extracted from the autologous tumor and expanded in IL-2; Treg, regulatory T cell.